Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Lineage Cell Therapeutics, Inc. Common Stock
(NY:
LCTX
)
1.850
+0.010 (+0.54%)
Official Closing Price
Updated: 8:00 PM EST, Mar 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Lineage Cell Therapeutics, Inc. Common Stock
< Previous
1
2
3
4
5
6
7
8
Next >
Lineage Cell Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
November 09, 2023
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Earnings Preview: Lineage Cell Therapeutics
↗
November 08, 2023
Via
Benzinga
Lineage Cell Therapeutics to Report Third Quarter 2023 Financial Results and Provide Business Update on November 9, 2023
November 01, 2023
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage Cell Therapeutics Earnings Preview
↗
August 09, 2023
Via
Benzinga
Lineage Cell Therapeutics: Q1 Earnings Insights
↗
May 11, 2023
Via
Benzinga
RG6501 (OpRegen®) Phase 1/2a Results to Be Featured at Eyecelerator at 2023 American Academy of Ophthalmology (AAO) Annual Meeting
October 24, 2023
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Are Longevity Stocks the Next Trillion-Dollar Industry? 3 Anti-Aging Picks
↗
October 17, 2023
Here are the best longevity stocks to consider. Each stock listed comes with their unique reasons to buy them.
Via
InvestorPlace
Lineage to Present at Cantor Fitzgerald 2023 Global Healthcare Conference on September 27, 2023
September 19, 2023
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage Announces Issuance of U.S. Patent Covering Proprietary Manufacturing and Differentiation Process for Retinal Pigmented Epithelial Cells
October 11, 2023
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
EXCLUSIVE: Cell Therapy Player Lineage Cell Therapeutics Starts Development Activities Under Licensing Pact With Eterna Therapeutics
↗
September 06, 2023
Lineage Cell Therapeutics Inc (NYSE: LCTX) has initiated certain development activities to generate a novel hypoimmune induced pluripotent stem cell (iPSC) line under the company’s exclusive option and...
Via
Benzinga
RG6501 (OpRegen®) Phase 1/2a Results Show Evidence of Rapid Improvement of Outer Retinal Structure in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
October 05, 2023
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage to Present at Baird 2023 Global Healthcare Conference and H.C. Wainwright & Co. 25th Annual Global Investment Conference
August 29, 2023
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
RG6501 (OpRegen®) Phase 1/2a Additional Results to Be Featured at 23rd EURETINA Congress
September 13, 2023
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Why DLocal Shares Are Trading Higher By 25%; Here Are 20 Stocks Moving Premarket
↗
August 16, 2023
Gainers
Via
Benzinga
Lineage to Present at 2023 International Spinal Research Trust Network Meeting
September 11, 2023
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage Cell Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
August 10, 2023
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership With Eterna Therapeutics
September 06, 2023
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage Cell Therapeutics to Report Second Quarter 2023 Financial Results and Provide Business Update on August 10, 2023
August 03, 2023
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Earnings Scheduled For August 10, 2023
↗
August 10, 2023
Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million.
Via
Benzinga
Lineage Cell Therapeutics' Lung Cancer Vaccine: Initial Data Reveals Modest, Durable Immune Response
↗
July 24, 2023
Lineage Cell Therapeutics Inc (NYSE: LCTX) and Cancer Research UK revealed primary and secondary endpoint results from the recently completed clinical study of VAC2 in advanced non-small
Via
Benzinga
Lineage Cell Therapeutics and Cancer Research UK Report Topline Phase 1 Study Results With VAC2 for the Treatment of Advanced Non-small Cell Lung Cancer
July 24, 2023
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage Cell Therapeutics Expected to Be Added to Russell 3000® Index
May 22, 2023
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage Cell Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
May 11, 2023
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage Receives Grant From California Institute for Regenerative Medicine (CIRM)
May 09, 2023
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage Cell Therapeutics to Report First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023
May 04, 2023
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
RG6501 (OpRegen®) Phase 1/2a Clinical Results Support the Potential for OpRegen to Slow, Stop or Reverse Disease Progression in Geographic Atrophy Secondary to Age-Related Macular Degeneration
April 26, 2023
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Harley-Davidson, Sportsman's Warehouse And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
↗
April 13, 2023
U.S. stock futures traded higher this morning. Here are some big stocks recording losses in today’s pre-market trading session.
Via
Benzinga
Lineage to Present at 2023 AAPS National Biotechnology Conference
April 18, 2023
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
3 Penny Stocks to Buy During Market Downturns
↗
April 10, 2023
If you're looking for penny stocks to buy that can weather economic turmoil, these should make the cut due to their strong fundamentals.
Via
InvestorPlace
Lineage and the Christopher & Dana Reeve Foundation Proudly Present the 1st Annual Spinal Cord Injury Investor Symposium
March 30, 2023
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
